Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 75   

Articles published

ARNA 4.12 0.00 (0.00%)
price chart
Belviq Sales Crack Critical Level
Sales of the anti-obesity Drug Belviq from Arena Pharmaceuticals (NASDAQ:ARNA) passed a critical level today with an improvement of 3.4% over the numbers last week.
Arena Pharmaceuticals Falls on Wider-than-Expected Q2 Loss
Arena Pharmaceuticals, Inc. (ARNA - Snapshot Report) fell approximately 3.7% after the company reported a net loss (excluding one-time items) of 12 cents per share in the second quarter of 2014 wider than the Zacks Consensus Estimate of loss of 11 cents.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Dips As Loss Goes Beyond ...  FinancialsTrend
One-Time Stock Sale Boosts Arena To Profit (ARNA)  Seeking Alpha (registration)
Related articles »  
Trading Volume Shifts: Image Sensing Systems, Inc.(NASDAQ:ISNS), Arena ...
Arena Pharmaceuticals, Inc.(NASDAQ:ARNA) gained seven cents to finish the day at a closing price of $4.25, a 1.67% increase in value from the previous closing price.
Related articles »  
Stocks Highlights: Quiksilver, Inc. (NYSE:ZQK), Arena Pharmaceuticals, Inc ...
Lakeway, NY - (MARKET NEWS CALL) - 8/29/2014� Specialpennystockalert.com, an investment community with a special focus on updating investors with recent news on the U.S.
Related articles »  
Advertising And The Belviq Re-Launch
July of 2014 marked the "re-launch" of the anti-obesity drug Belviq from Arena Pharmaceuticals (NASDAQ:ARNA) and marketing partner Eisai (OTCPK:ESALY). Belviq had its initial launch in June of ... Needless to say, Arena stock suffered because sales ...
Related articles »  
Stock Runners: Arena Pharmaceuticals (NASDAQ:ARNA), AT&T, Inc. (NYSE:T ...
On 1 AUG Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) issued its quarterly earnings data on Friday. The company reported $0.03 earnings per share for the quarter, beating the analysts' consensus estimate of ($0.11) by $0.14.
Concerns on Biotech Stocks- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) [Trend Analysis] recently delivered Belviq sales of $3.5M (including $0.4 million from the 15-day free trial voucher redemption).
Related articles »  
Hot Stocks: Zynga Inc(NASDAQ:ZNGA), Arena Pharmaceuticals, Inc.(NASDAQ ...
Zynga Inc(NASDAQ:ZNGA) gained one cent to move to a new closing price of $2.89, a 0.52% increase in value from the previous closing price.
Related articles »  
Shining on Major News: Google Inc (NASDAQ:GOOG), Arena Pharmaceuticals ...
On 1 AUG Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) reported financial results for the second quarter ended June 30, 2014.
Related articles »  
Arena Pharmaceuticals Receives Consensus Rating of �Hold� from Brokerages ...
Arena Pharmaceuticals (NASDAQ:ARNA) last announced its earnings results on Friday, August 1st. The company reported $0.03 earnings per share for the quarter, beating the analysts' consensus estimate of ($0.11) by $0.14.
Volatile Stocks to Watch - dELiA*s, Inc.(NASDAQ:DLIA),Arena Pharmaceuticals ...  Techsonian (press release)
Related articles »